为您找到相关结果约160个

你是不是要搜索 期刊ALKS 3831 点击跳转

EFFECTS OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF ALKS 3831, A COMBINATION OF OLANZAPINE AND SAMIDORPHAN

Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan

Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2

OF EFFECT OF ITRACONAZOLE ON PHARMACOKINETICS OF OLANZAPINE AND SAMIDORPHAN GIVEN IN COMBINATION AS ALKS3831

Modeling Prediction of Systemic Exposure of Olanzapine and Samidorphan When Administered in Combination as ALKS3831 in Pediatric Subjects

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared

ALKS 3831, a combination of olanzapine and samidorphan, has no clinically relevant effect on QT prolongation

A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH

ALKS 3831, A COMBINATION OF OLANZAPINE AND SAMIDORPHAN, DOES NOT HAVE A CLINICALLY RELEVANT EFFECT ON

A PHASE 3, MULTICENTER STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF ALKS 3831 IN

MULTIPLE-DOSE PHARMACOKINETICS AND SAFETY OF ALKS 3831, A FIXED DOSE COMBINATION OF OLANZAPINE AND SAMIDORPHAN

A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM

A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients With

A study comparing weight gain from ALKS 3831 to olanzapine in early-illness young adults with schizophrenia

and CYP1A2 Inhibition or Induction on Exposure of Olanzapine and Samidorphan Given in Combination as ALKS3831

为您找到相关结果约160个

共160条页码: 1/11页15条/页